The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.

<h4>Background</h4>Most individuals developing tuberculosis (TB) are working age adults living in low- and middle-income countries (LMICs). The resulting disability and death impact economic productivity and burden health systems. New TB vaccine products may reduce this burden. In this s...

Full description

Saved in:
Bibliographic Details
Main Authors: Allison Portnoy, Jean-Louis Arcand, Rebecca A Clark, Chathika K Weerasuriya, Christinah Mukandavire, Roel Bakker, Edith Patouillard, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G White, Nicolas A Menzies
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-07-01
Series:PLoS Medicine
Online Access:https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004252&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846127113479913472
author Allison Portnoy
Jean-Louis Arcand
Rebecca A Clark
Chathika K Weerasuriya
Christinah Mukandavire
Roel Bakker
Edith Patouillard
Nebiat Gebreselassie
Matteo Zignol
Mark Jit
Richard G White
Nicolas A Menzies
author_facet Allison Portnoy
Jean-Louis Arcand
Rebecca A Clark
Chathika K Weerasuriya
Christinah Mukandavire
Roel Bakker
Edith Patouillard
Nebiat Gebreselassie
Matteo Zignol
Mark Jit
Richard G White
Nicolas A Menzies
author_sort Allison Portnoy
collection DOAJ
description <h4>Background</h4>Most individuals developing tuberculosis (TB) are working age adults living in low- and middle-income countries (LMICs). The resulting disability and death impact economic productivity and burden health systems. New TB vaccine products may reduce this burden. In this study, we estimated the impact of introducing novel TB vaccines on gross domestic product (GDP) growth in 105 LMICs.<h4>Methods and findings</h4>We adapted an existing macroeconomic model to simulate country-level GDP trends between 2020 and 2080, comparing scenarios for introduction of hypothetical infant and adolescent/adult vaccines to a no-new-vaccine counterfactual. We parameterized each scenario using estimates of TB-related mortality, morbidity, and healthcare spending from linked epidemiological and costing models. We assumed vaccines would be introduced between 2028 and 2047 and estimated incremental changes in GDP within each country from introduction to 2080, in 2020 US dollars. We tested the robustness of results to alternative analytic specifications. Both vaccine scenarios produced greater cumulative GDP in the modeled countries over the study period, equivalent to $1.6 (95% uncertainty interval: $0.8, 3.0) trillion for the adolescent/adult vaccine and $0.2 ($0.1, 0.4) trillion for the infant vaccine. These GDP gains were substantially lagged relative to the time of vaccine introduction, particularly for the infant vaccine. GDP gains resulting from vaccine introduction were concentrated in countries with higher current TB incidence and earlier vaccine introduction. Results were sensitive to secular trends in GDP growth but relatively robust to other analytic assumptions. Uncertain projections of GDP could alter these projections and affect the conclusions drawn by this analysis.<h4>Conclusions</h4>Under a range of assumptions, introducing novel TB vaccines would increase economic growth in LMICs.
format Article
id doaj-art-c05dd181e1f84e7cb5fd5e5ebc0e3787
institution Kabale University
issn 1549-1277
1549-1676
language English
publishDate 2023-07-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Medicine
spelling doaj-art-c05dd181e1f84e7cb5fd5e5ebc0e37872024-12-12T05:30:53ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762023-07-01207e100425210.1371/journal.pmed.1004252The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.Allison PortnoyJean-Louis ArcandRebecca A ClarkChathika K WeerasuriyaChristinah MukandavireRoel BakkerEdith PatouillardNebiat GebreselassieMatteo ZignolMark JitRichard G WhiteNicolas A Menzies<h4>Background</h4>Most individuals developing tuberculosis (TB) are working age adults living in low- and middle-income countries (LMICs). The resulting disability and death impact economic productivity and burden health systems. New TB vaccine products may reduce this burden. In this study, we estimated the impact of introducing novel TB vaccines on gross domestic product (GDP) growth in 105 LMICs.<h4>Methods and findings</h4>We adapted an existing macroeconomic model to simulate country-level GDP trends between 2020 and 2080, comparing scenarios for introduction of hypothetical infant and adolescent/adult vaccines to a no-new-vaccine counterfactual. We parameterized each scenario using estimates of TB-related mortality, morbidity, and healthcare spending from linked epidemiological and costing models. We assumed vaccines would be introduced between 2028 and 2047 and estimated incremental changes in GDP within each country from introduction to 2080, in 2020 US dollars. We tested the robustness of results to alternative analytic specifications. Both vaccine scenarios produced greater cumulative GDP in the modeled countries over the study period, equivalent to $1.6 (95% uncertainty interval: $0.8, 3.0) trillion for the adolescent/adult vaccine and $0.2 ($0.1, 0.4) trillion for the infant vaccine. These GDP gains were substantially lagged relative to the time of vaccine introduction, particularly for the infant vaccine. GDP gains resulting from vaccine introduction were concentrated in countries with higher current TB incidence and earlier vaccine introduction. Results were sensitive to secular trends in GDP growth but relatively robust to other analytic assumptions. Uncertain projections of GDP could alter these projections and affect the conclusions drawn by this analysis.<h4>Conclusions</h4>Under a range of assumptions, introducing novel TB vaccines would increase economic growth in LMICs.https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004252&type=printable
spellingShingle Allison Portnoy
Jean-Louis Arcand
Rebecca A Clark
Chathika K Weerasuriya
Christinah Mukandavire
Roel Bakker
Edith Patouillard
Nebiat Gebreselassie
Matteo Zignol
Mark Jit
Richard G White
Nicolas A Menzies
The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
PLoS Medicine
title The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
title_full The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
title_fullStr The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
title_full_unstemmed The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
title_short The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
title_sort potential impact of novel tuberculosis vaccine introduction on economic growth in low and middle income countries a modeling study
url https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004252&type=printable
work_keys_str_mv AT allisonportnoy thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT jeanlouisarcand thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT rebeccaaclark thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT chathikakweerasuriya thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT christinahmukandavire thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT roelbakker thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT edithpatouillard thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT nebiatgebreselassie thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT matteozignol thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT markjit thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT richardgwhite thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT nicolasamenzies thepotentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT allisonportnoy potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT jeanlouisarcand potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT rebeccaaclark potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT chathikakweerasuriya potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT christinahmukandavire potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT roelbakker potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT edithpatouillard potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT nebiatgebreselassie potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT matteozignol potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT markjit potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT richardgwhite potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy
AT nicolasamenzies potentialimpactofnoveltuberculosisvaccineintroductiononeconomicgrowthinlowandmiddleincomecountriesamodelingstudy